Skip to main content

CNS Pharmaceuticals, Inc.

CNSP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001729427

In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding CNS Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of CNSP: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders118−3
Shares512.8K24.6K−488.1K (−95.2%)
Value$421.8K$221.5K−$200.3K (−47.5%)

New holders (4)

Institutions that held CNS Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to CNSP in Q3 2025
InstitutionSharesValue% of portfolio
DRW Securities, LLC14,050$126.5K0.01%
Morgan Stanley28$2520.00%
Citigroup Inc2$180.00%
Danske Bank A/S1$90.00%

Sold out (7)

Institutions that held CNS Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of CNSP in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
Armistice Capital, LLC406,000$334.9K
Virtu Financial LLC23,348$19.0K
Geode Capital Management, LLC17,871$14.7K
Two Sigma Securities, LLC15,633$12.9K
HRT Financial LP10,863$8.00K
Tower Research Capital LLC (TRC)6,738$5.56K
SBI Securities Co., Ltd.13$11